NEW YORK – Myriad Genetics announced Thursday that it entered into a cross-licensing agreement with Personalis covering their minimal residual disease (MRD) technology patent estates.
The companies say the agreement will bolster their ability to operate in the MRD space and will broaden cancer patient access to MRD testing, which can detect tumor recurrence and monitor patient treatment response. They further aim to establish MRD testing as a standard of care.
"We believe that our unique sets of capabilities and inclusive approach to using intellectual property for the benefit of patients will help drive broader MRD testing adoption, reimbursement, and greatly advance this opportunity for patients in this emerging and under-penetrated market," Paul Diaz, president and CEO of Myriad, said in a statement.
Financial and other details of the agreement were not provided.
Last year, Myriad partnered with Personalis to market Personalis' ImmunoID NeXt immunogenomics biomarker discovery platform to pharmaceutical partners using Myriad's MyRisk Hereditary Cancer Test, BRACAnalysis CDx, and/or MyChoice CDx assays.
Personalis recently settled an MRD testing patent infringement lawsuit with Foresight Diagnostics.